Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.

Saved in:
Bibliographic Details
Title: Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.
Authors: Kim DH; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Kwon S; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Cha S; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Öz RS; Department of Internal Medicine, Hacettepe University Hospital, Ankara, Turkiye., Hong J; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Shin DY; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Yoon SS; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Byun JM; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, KoreaBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Source: Therapeutic advances in hematology [Ther Adv Hematol] 2025 Dec 22; Vol. 16, pp. 20406207251406461. Date of Electronic Publication: 2025 Dec 22 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101549589 Publication Model: eCollection Cited Medium: Print ISSN: 2040-6207 (Print) Linking ISSN: 20406207 NLM ISO Abbreviation: Ther Adv Hematol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41445759
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kim+DH%22">Kim DH</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Kwon+S%22">Kwon S</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Cha+S%22">Cha S</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Öz+RS%22">Öz RS</searchLink>; Department of Internal Medicine, Hacettepe University Hospital, Ankara, Turkiye.<br /><searchLink fieldCode="AU" term="%22Hong+J%22">Hong J</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Shin+DY%22">Shin DY</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Koh+Y%22">Koh Y</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Yoon+SS%22">Yoon SS</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Byun+JM%22">Byun JM</searchLink>; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, KoreaBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101549589%22">Therapeutic advances in hematology</searchLink> [Ther Adv Hematol] 2025 Dec 22; Vol. 16, pp. 20406207251406461. <i>Date of Electronic Publication: </i>2025 Dec 22 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage%22">Sage </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101549589 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2040-6207 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220406207%22">20406207 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Hematol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41445759
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/20406207251406461
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 20406207251406461
    Titles:
      – TitleFull: Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kim DH
      – PersonEntity:
          Name:
            NameFull: Kwon S
      – PersonEntity:
          Name:
            NameFull: Cha S
      – PersonEntity:
          Name:
            NameFull: Öz RS
      – PersonEntity:
          Name:
            NameFull: Hong J
      – PersonEntity:
          Name:
            NameFull: Shin DY
      – PersonEntity:
          Name:
            NameFull: Koh Y
      – PersonEntity:
          Name:
            NameFull: Yoon SS
      – PersonEntity:
          Name:
            NameFull: Byun JM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 12
              Text: 2025 Dec 22
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2040-6207
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Therapeutic advances in hematology
              Type: main
ResultId 1